Modified epitopes for boosting CD4+ T-cell responses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 26, 2021
Grant Date -
Dec 18, 2014
app pub date -
Jan 30, 2013
filing date -
Jan 30, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2013 Application Filing Year
- A61K Class
- 12711 Applications Filed
- 11051 Patents Issued To-Date
- 86.95 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 2 Citation Count
- A61K Class
- 75.37 % this patent is cited more than
- 4 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jul 26, 2028 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jul 26, 2032 |
